European Medicines Agency

Despite industry’s endless lip service to driving innovation for the benefit of patients, many diseases go untreated. Now, sick of being passive recipients, patients are taking control and shaping innovation to their real needs

The EMA says Amsterdam Molecular Therapeutics’ Glybera for treating a serious enzyme deficiency, is not ready for approval

The 68,000 members of the European Society of Cardiology want a single, co-ordinated and rigorous system to oversee the evaluation of medical devices

As the second tranche of projects in the €2 billion Innovative Medicines Initiative was announced this week, a quick stock take of progress to date hints at what this wide-ranging collaboration could deliver

A new campaign seeks to persuade regulators to set new rules for approving personalised treatments that are currently in clinical development.